Eikon Therapeutics completed an upsized IPO in February 2026, raising $381 million to fund its clinical programs. The company finished enrollment in a Phase 2 trial for EIK1001 in first-line treatment of stage 4 non-small cell lung cancer and is progressing trials for next-gen PARP1 inhibitors and a WRN helicase inhibitor. Financially, Eikon reported a net loss of $333.6 million for 2025, with increased R&D and administrative expenses due to expanded clinical activities and new headquarters. The company expects its cash position to support operations into late 2027 and anticipates data from key trials in the second half of 2026.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
